MAZDUTIDE 10mg

MAZDUTIDE 10mg
£80.00

(NOT FOR HUMAN CONSUMPTION RESEARCH USE ONLY) 

Mazdutide

(also known as IBI362 or LY3305677) is an investigational, long-acting synthetic peptide that acts as a dual agonist for both the GLP-1 (glucagon-like peptide-1) and glucagon receptors. Developed through a partnership between Eli Lilly and Innovent Biologics, it is a mammalian oxyntomodulin analogue. 

 

Mechanism of Action

Unlike single-target drugs like semaglutide (Wegovy), mazdutide uses a "dual-action" approach to target metabolism: 

  • GLP-1 Receptor Agonism: Mimics gut hormones to reduce appetite, slow digestion, and stimulate insulin secretion.
  • Glucagon Receptor Agonism: Directly targets the liver to increase energy expenditure and promote fat oxidation (burning fat).
  • Synergy: While glucagon can raise blood sugar, the GLP-1 component counteracts this, allowing the drug to boost calorie burning while effectively lowering glucose levels. 

 

Clinical Efficacy and Trial Results

Clinical data, primarily from Phase 3 trials in Chinese populations, shows robust weight loss and metabolic improvements. 

  • Weight Loss: In the GLORY-1 trial, participants on a 6 mg dose achieved a mean weight reduction of 14% over 48 weeks. Higher doses (9 mg) led to weight reductions of 18.6% to 20% at 60 weeks.
  • Superiority over Existing Meds: Phase 3 DREAMS trialsfound mazdutide superior to dulaglutide and semaglutide in both glycaemic control and weight reduction for patients with type 2 diabetes.
  • Liver and Metabolic Health: Trials observed significant reductions in waist circumference, blood pressure, and liver fat content (up to 70% reduction in some groups). 

 

Regulatory Status and Safety

  • Approval Status: In 2025, mazdutide received its first global approval from China's National Medical Products Administration (NMPA) for chronic weight management and type 2 diabetes.
  • Global Availability: As of January 2026, it is not yet approved by the FDA (US) or MHRA (UK) for general medical use. Larger international trials are ongoing to support global regulatory filings.
  • Common Side Effects: Adverse events are primarily gastrointestinal, including nausea, diarrhoea, and vomiting, which are mostly mild and occur during the dose-escalation phase.